Immune checkpoint inhibitors in sinonasal squamous cell carcinoma
Authors:
- 12 May 2020
- journal article
- letter
- Published by Elsevier in Oral Oncology
- Vol. 109, 104776
Abstract
No abstract availableFunding Information
- American Head and Neck Society
This publication has 5 references indexed in Scilit:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009Cancer, 2013
- Incidence and survival in patients with sinonasal cancer: A historical analysis of population‐based dataHead & Neck, 2011